Page 19 Volume 18 - N.4 - 2010

Dor (2010) 18
management. Em: Pichler WJ, ed. Drug hypersensitivity. Basel: Karg- 30. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Clinical patterns
er; 2007. p. 340-9. of hypersensitivity to nonesteroidal anti-inflammatory drugs and their
4. Jenneck C, Juergens U, Buecheler M, Novak N. Pathogenesis, di- pathogenesis. J Allergy Clin Immunol. 1977;60:276-84.
agnosis, and treatment of aspirin intolerance. Ann Allergy Asthma 31. Delaney JC. The diagnosis of aspirin idiosyncrasy by analgesic
Immunol. 2007;99:13-21. challenge. Clin Allergy. 1976;6:177-81.
5. Gaspar A, Piedade S, Morais de Almeida M. Alergia IgE-mediada 32. Falliers CJ. Acetaminophen and aspirin challenges in sub-groups of
ao metamizol. Rev Port Imunoalergologia. 2009;17(Supl 2):77. asthmatics. J Asthma. 1983;20:39-49.
6. Gomes E, Cardoso MF, Praça F, Gomes L, Mariño E, Demoly P. Self- 33. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxyge-
reported drug allergy in a general adult Portuguese population. Clin nase-1 variant inhibited by acetaminophen and other analgesic/
Exp Allergy. 2004;34:1597-601. antipyretic drugs: cloning, structure and expression. Proc Natl Acad
7. Settipane RA, Constantine HP, Settipane GA. Aspirin intolerance and Sci USA. 2002;99:13926-31.
recurrent urticaria in normal adults and children. Epidemiology and 34. Senna GE, Passalacqua G, Andri G, et al. Nimesulide in the treat-
review. Allergy. 1980;35:149-54. ment of patients intolerant of aspirin and other NSAIDs. Drug Saf.
8. Widal MF, Abramin P, Lermoyez J. Anaphylaxie et idiosyncrasie. 1996;14:94-103.
Presse Med. 1922;30:189-92. 35. Bianco S, Robuschi M, Petrigni G, et al. Efficacy and tolerability of
9. Samter M, Beers RF. Intolerance to aspirin: clinical studies and con- nimesulide in asthmatic patients intolerant to aspirin. Drugs.
sideration of its pathogenesis. Ann Intern Med. 1968;68:975-83. 1993;46(Suppl 1):115-20.
10. Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of 36. Faria E, Tomás MR, Carrapatoso I, et al. Intolerância aos anti-infla-
allergic and pseudoallergic reactions to drugs that inhibit cyclooxy- matórios não esteróides: atitude diagnóstica e alternativa terapêu-
genase enzymes. Ann Allergy Asthma Immunol. 2001;87:177-80. tica. Via pneumológica. 1995;8:47-57.
11. Stevenson DD. Hypersensitivity reactions to NSAIDs. J Investig Al- 37. Andri L, Senna G, Betteli C, et al. Tolerability of nimesulide in aspirin-
lergol Clin Immunol. 2009;19(Suppl 3):3-9. sensitive patients. Ann Allergy. 1994;72:29-32.
12. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene 38. Noble S, Balfour JA. Meloxicam. Drugs. 1996;51:424-30.
E4 concentrations increase after aspirin challenge in aspirin-sensi- 39. Wojtulewski JA, Schattenkirchner M, Barceló P, et al. A six-moths

tive asthmatic subjects. Am Rev Resp Dis. 1991;143:1025-9. double-blind trial to compare the efficacy and safety of meloxicam
13. Sladek K, Dworski R, Soja J, et al. Eicosanoids in broncheoalveolar 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid
lavage fluid of aspirin-intolerant patients with asthma after aspirin arthritis. Br J Rheumatol. 1996;35(Suppl 1):22-8.
challenge. Am J Respir Crit Care Med. 1994;149:940-6. 40. Lindén B, Distel M, Bluhmki E. A double-blind study to compare the ef-
14. Picado C, Ramis I, Rosellò J, et al. Release of peptide leukotriene ficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients
into nasal secretions after local instillation of aspirin in aspirin sensi- with osteoarthritis of the hip. Br J Rheumatol. 1996;35(Suppl 1):35-8.
tive asthmatic patients. Am Rev Respir Dis. 1992;145:65-9. 41. Quaratino D, Romano A, Di Fonso M, et al. Tolerability of meloxicam
15. Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD. Association of in patients with histories of adverse reactions to nonsteroidal anti-
urinary leukotriene E4 excretion during aspirin challenges with severity inflammatory drugs. Ann Allergy Asthma Immunol. 2000;84:613-7.
of respiratory responses. J Allergy Clin Immunol. 1999;104:559-64. 42. Nettis E, Di Paola R, Ferrannini A, Tursi A. Meloxicam in hypersen-
16. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy. sitivity to NSAIDs. Allergy. 2001;56:803-4.
1988;18:15-20. 43. Sánchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Pérez CR.
17. Dekker JW, Nizankowska E, Schmitz-Schumann M, et al. Aspirin- Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with
induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp cutaneous reactions. Ann Allergy Asthma Immunol. 2001;87:201-4.
Allergy. 1997;27:574 -7. 44. Malheiro D, Cadinha S, Rodrigues J, Castel-Branco MG. Hipersen-
18. Kim SH, Park HS. Genetic markers for differentiating aspirin hyper- sibilidade a AINEs: o papel dos inibidores da COX-2 como fármacos
sensitivity. Yonsei Med J. 2006;47:15-21. alternativos. Rev Port Imunoalergologia. 2005;13:243-50.
19. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglan- 45. Gala Ortiz G, Fernández Ordóñez R. Tolerancia a meloxicam en
din endoperoxide synthase (cyclooxygenase) isozymes by aspirin pacientes intolerantes a antinflamatorios no esteroideos. Alergol
and other non-steroidal anti-inflammatory drugs. J Biol Chem. Inmunol Clin. 2003;18:275-9.
1993;268:6610-4. 46. Morais-Almeida M, Marinho S, Rosa S, Gaspar A, Rosado-Pinto JE.
20. Churchill L, Graham A, Shih CK, Pauletti D, Farina PR, Grob P. Selec- Multiple drug intolerance including etoricoxib. Allergy. 2006; 61:144-5.
tive inhibition of human cyclo-oxygenase-2 by meloxicam. Inflam- 47. Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical
mopharmacology. 1996;4:125-35. evidence that aspirin-intolerant asthmatic subjects tolerate the cy-
21. Estrada Rodríguez JL, Florido López JF, Belchi Hernández J, et al. clooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin
Asthma in children and ASA intolerance. J Investig Allergol Clin Immunol. 2003;111:1116-21.
Immunol. 1993;3:315-20. 48. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Short-term and long-term
22. Quiralte J. Las reacciones a AINEs: fenotipos clínicos y tratamiento. tolerability of rofecoxib in patients with prior reactions to nonsteroidal
J Investig Allergol Clin Immunol. 2009;19(Suppl 3):41-4. anti-inflammatory drugs. Ann Allergy Asthma Immunol. 2005;94:29-33.
23. Kowalski ML, Bienkiewicz B, Woszczek G, Iwaszkiewicz J, Ponia- 49. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. Safety of etori-
towska M. Diagnosis of pyrazolone drug sensitivity: clinical history coxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients
versus skin testing and in vitro testing. Allergy Asthma Proc. with aspirin-exacerbated respiratory disease. Ann Allergy Asthma
1999;20:347-52. Immunol. 2006;97:105-9.
24. Sanz ML, Gamboa PM, De Weck AL. Cellular tests in the diagnosis 50. Pagani M, Bonadonna P, Dama A, Senna GE, Vescovi PP, Antico A.
of drug hypersensitivity. Curr Pharm Des. 2008;14:2803-8. Long-term tolerability of etoricoxib in different types of NSAID-intol-
25. Sanz ML, Gamboa PM, García-Avilés C, De Weck A. Drug hyper- erant subjects. Eur Ann Allergy Clin Immunol. 2010;42:216-20.
sensitivities: which room for biological tests? Eur Ann Allergy Clin 51. Muratore L, Ventura M, Calogiuri G, et al. Tolerance to etoricoxib in 37
Immunol. 2005;37:230-5. patients with urticaria and angioedema induced by nonsteroidal anti-
26. Nizankowska-Mogilnicka E, Bochenek G, Mastalerz L, et al. EAACI/ inflammatory drugs. Ann Allergy Asthma Immunol. 2007;98:168-71.
GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin 52. Gollapudi RR, Teirstein PS, Stevenson DD, Simon RA. Aspirin sen-
hypersensitivity. Allergy. 2007;62:1111-8. sitivity: implications for patients with coronary artery disease. JAMA.
27. Settipane RA, Schrank PJ, Simon RA, Mathison DA, Christiansen SC, 2004;292:3017-23.
Stevenson DD. Prevalence of cross-sensitivity with acetaminophen 53. Rossini R, Angiolillo DJ, Musumeci G, et al. Aspirin desensitization
in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol. in patients undergoing percutaneous coronary interventions with
1995;96:480-5. stent implantation. Am J Cardiol. 2008;101:786-9.
28. Morais de Almeida M, Gaspar A, Carvalho F, Abreu Nogueira J, Ro- 54. Alijotas-Reig J, San Miguel-Moncín M, Cisteró-Bahíma A. Aspirin
sado Pinto J. Adverse reactions to acetaminophen, ASA, and NSAIDs desensitization in the treatment of antiphospholipid syndrome during
in children: what alternatives? Allergy Asthma Proc. 1997;18:313-8. pregnancy in ASA-sensitive patients. Am J Reprod Immunol.
29. Morais-Almeida M, Marinho S, Gaspar A. Montelukast in 2 atopic 2006;55:45-50.
patients with intolerance to nonsteroidal anti-inflammatory drugs and 55. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for
paracetamol: 5-year follow-up. J Investig Allergol Clin Immunol. aspirin desensitization treatment in patients with aspirin-exacerbated
2007;17:278-9. respiratory disease. J Allergy Clin Immunol. 2007;119:157-64.

DOR

18